Items where authors include "Greystoke, A."

Article

Walker, K. orcid.org/0000-0001-6922-9100, Hinsley, S., Phillip, R. orcid.org/0000-0002-9604-9276 et al. (6 more authors) (2022) Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology, 6 (6). e2200133. ISSN 2473-4284

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Salem, A., Franks, K., Greystoke, A. et al. (6 more authors) (2022) Unaccounted confounders limit the ability to draw conclusions from big data analysis comparing radiotherapy fractionation regimens in NSCLC. Journal of Thoracic Oncology, 17 (6). e55-e56. ISSN 1556-0864

Gomes, F., Lewis, A., Morris, R. et al. (33 more authors) (2020) The care of older cancer patients in the United Kingdom. ecancermedicalscience, 14. 1101.

Conference or Workshop Item

Horne, A., Ali, A., Brown, S. et al. (28 more authors) (2022) 153 CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). In: 20th Annual British Thoracic Oncology Group Conference 2022, 27-28 Jan 2022, Virtual.

Proceedings Paper

Walls, G., Horne, A., Harrow, S. et al. (17 more authors) (2025) 3513: ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: interim report from the CONCORDE phase Ib trial (NCT04550104). In: Radiotherapy and Oncology. ESTRO 2025, 02-06 May 2025, Vienna, Austria. , s1395-s1397.

Horne, A., Walls, G., Brown, S. et al. (17 more authors) (2025) An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRIs) in combination with conventional radiotherapy in NSCLC. In: Journal of Thoracic Oncology. European Lung Cancer Congress 2025, 26-29 Mar 2025, Paris, France. Elsevier BV , S150.

Walls, G., Horne, A., Franks, K. et al. (23 more authors) (2025) 255 An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRis) in combination with conventional radiotherapy in NSCLC. In: Lung Cancer. 23rd BTOG Annual Conference 2025, 03-05 Mar 2025, Belfast, Northern Ireland. Elsevier BV , p. 108364.

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .

Horne, A., Brown, S., Gilbert, A. et al. (16 more authors) (2024) Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm. In: Radiotherapy and Oncology. ESTRO 2024, 03-07 May 2024, Glasgow, UK. , S1652-S1655.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier BV , S296-S297.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier , S296-S297.

Hanna, G., McDonald, F., Greystoke, A. et al. (7 more authors) (2017) EP-1228 : UK NCRI CTRad consensus on drug and radiotherapy combination platform studies in NSCLC. In: Radiotherapy and Oncology. ESTRO 36 - European Society for Radiotherapy & Oncology, 05-09 May 2017, Vienna, Austria. Elsevier , S662-S663.